Navigation Links
Postdiagnosis aspirin use reduces risk of dying from colorectal cancer
Date:8/11/2009

Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital (MGH), Dana-Farber Cancer Institute and Brigham and Women's Hospital. In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.

"While previous studies by our group and others showed that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of developing colorectal cancer, this study is the among the first to show that aspirin can also improve survival in patients who have already been diagnosed with colorectal cancers. Moreover, the benefit appeared to be especially strong among patients with cancers that express COX-2," says Andrew Chan, MD, MPH, of the MGH Gastrointestinal Unit, the study's lead author. "This is an important first step toward developing targeted approaches to improving patient outcomes."

Many previous studies have shown that regular use of aspirin and other non-steroidal anti-inflammatory drugs reduces the risk of developing colorectal cancer. In 2007, the same MGH/DFCI research team found that the benefit only applied to tumors overexpressing COX-2, an enzyme believed to drive tumor growth and known to be inhibited by aspirin and related drugs. To test their hypotheses that aspirin would also improve the survival of patients diagnosed with colorectal cancer, again through its inhibition of COX-2, the researchers compiled data from two ongoing prospective research studies the Nurses Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS). Both studies gather comprehensive health information on their participants every two years; data are then analyzed for associations between factors such as medication use and the incidence of several diseases.

The current study focused on 1,279 study participants who were diagnosed with stage 1, 2 or 3 colorectal cancer during their participation in the studies for whom data was available on aspirin use before and after diagnosis. Tumor samples available from 459 participants were analyzed for the expression of COX-2. Study results indicated that patients who regularly took aspirin after their diagnosis had a nearly 30 percent lower risk of dying of colorectal cancer during an average of 11 years after diagnosis than did non-aspirin users. The benefit was especially strong among patients who began using aspirin after diagnosis. In contrast, patients who were aspirin users before diagnosis did not appear to benefit as much from continuing aspirin use after diagnosis. As expected, the survival benefit appeared restricted to patients with COX-2-positive tumors.

"We believe our results could lead to improvements in the therapy of patient with colon cancer," says Charles Fuchs, MD, MPH, of Dana-Farber, the study's senior author. "We're now following up this observational study with a randomized trial to evaluate adding the COX-2 inhibitor celecoxib which is less likely to have the gastrointestinal side effects of aspirin to standard chemotherapy."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Aspirin May Stem Deaths From Colorectal Cancer
2. Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting
3. Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin
4. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
5. Value of Taking Aspirin to Cut Heart Risk Varies
6. Chewable Aspirin More Readily Absorbed
7. Study compares formulations of 3 aspirin types
8. Study compares formulations of three aspirin types
9. Aspirin Lowers Stroke Risk in Peripheral Artery Disease
10. Aspirin Linked to Brain Microbleeds
11. Plavix Plus Aspirin Lowers Stroke Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Marietta, GA (PRWEB) , ... April 25, 2017 ... ... implant and instrument solutions, announces the continuation of its strategic partnership with and ... surgeons in developing nations in the safe and effective management of complex spine ...
(Date:4/24/2017)... WASHINGTON, DC (PRWEB) , ... April 24, 2017 , ... ... was recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, ... the Santana Telehealth Project for using telemedicine to improve the lives of the poor ...
(Date:4/24/2017)... Antonio, TX (PRWEB) , ... April 24, 2017 , ... ... by the glitterati, those unreal icons inhabiting the rarified air of pop and film ... the paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from ...
(Date:4/24/2017)... ... 24, 2017 , ... Veteran Theresa James awoke to the sound of her ... In “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were ... conversations and situations throughout my divorce,” James said. “After the death of my children, ...
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... , April 18, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a CAGR ... Global Arthroscopy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
Breaking Medicine Technology: